SCHEMBL1348932

SCHEMBL1348932

CC(=O)NC(=N)N(C)CC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MVD P53602 1/20 0.32
TDP1 Q9NUW8 2/20 0.31
EYA2 O00167 1/20 0.31
APP P05067 1/20 0.31
ACE P12821 1/20 0.31
CRBN Q96SW2 1/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
CHRM2 P08172 1/20 0.30
ADRA2A P08913 1/20 0.30
ALOX15 P16050 1/20 0.30
TSHR P16473 1/20 0.30
DRD1 P21728 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
CYP2C19 P33261 1/20 0.30
ADRA1A P35348 1/20 0.30
DRD3 P35462 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16274513 0.85 CRBN (0.32) CRBN
SCHEMBL26247427 0.80 MEN1 (0.34) MVD
SCHEMBL9437064 0.78 TDP1 (0.33) MVDTDP1EYA2APPACE
SCHEMBL3893329 0.77 HDAC3 (0.38) LMNA
SCHEMBL17040289 0.76 SMN1; SMN2 (0.35) ACEKDM4ETSHR
SCHEMBL9216352 0.75
SCHEMBL9426270 0.74 CTSS (0.36) TDP1
SCHEMBL14558869 0.73 MVD (0.31) MVDTDP1EYA2APPACE
SCHEMBL14424094 0.73 MVD (0.31) MVDTDP1EYA2APPACE
Water SCHEMBL27985983 0.73 MVD (0.31) MVDTDP1EYA2APPACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218555-A1 CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF YU RUEY J (US) 2023-07-13 US claimed
US-11642328-B2 Creatine, its derivatives, compositions and methods of use thereof YU RUEY J (US) 2023-05-09 US claimed
US-9642825-B2 Bio-available N-acetyl creatine species and compositions thereof ENERGY BEVERAGES LLC 2017-05-09 US claimed
US-20150238453-A1 BIO-AVAILABLE N-ACETYL CREATINE SPECIES AND COMPOSITIONS THEREOF 4141 HOLDINGS, LLC (US) 2015-08-27 US claimed
US-8476223-B2 Metallo-lactoferrin-coenzyme compositions to improve sleep patterns NAIDU LP (US) 2013-07-02 US claimed
US-20110200575-A1 METALLO-LACTOFERRIN-COENZYME COMPOSITIONS TO IMPROVE SLEEP PATTERNS NAIDU LP (US) 2011-08-18 US claimed
US-7956031-B2 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy NAIDU LP (US) 2011-06-07 US claimed
US-20070253941-A1 Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof NAIDU LP 2007-11-01 US claimed
US-20060269535-A1 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy NAIDU LP 2006-11-30 US claimed
US-11813237-B2 Creatine, its derivatives, compositions and methods of use thereof YU RUEY J (US) 2023-11-14 US disclosed
US-20230218555-A1 CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF YU RUEY J (US) 2023-07-13 US disclosed
US-11642328-B2 Creatine, its derivatives, compositions and methods of use thereof YU RUEY J (US) 2023-05-09 US disclosed
US-20220401398-A1 CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF YU RUEY J (US) 2022-12-22 US disclosed
US-20220323388-A1 CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF YU RUEY J (US) 2022-10-13 US disclosed
US-20110286986-A1 LACTOFERRIN AND ANGIOGENIN COMPOSITIONS AND USES THEREOF NAIDU LP (US) 2011-11-24 US disclosed
US-8021659-B2 Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof NAIDU LP (US) 2011-09-20 US disclosed
US-20110200575-A1 METALLO-LACTOFERRIN-COENZYME COMPOSITIONS TO IMPROVE SLEEP PATTERNS NAIDU LP (US) 2011-08-18 US disclosed
US-7956031-B2 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy NAIDU LP (US) 2011-06-07 US disclosed
US-20070253941-A1 Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof NAIDU LP 2007-11-01 US disclosed
US-20060269535-A1 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy NAIDU LP 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150238453-A1 BIO-AVAILABLE N-ACETYL CREATINE SPECIES AND COMPOSITIONS THEREOF CKMT1A; CKMT1B, RIMKLA, CRAT MVD 4668/4885TDP1 3222/4885EYA2 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.